<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article306</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/BRIM-3" style="display:block; margin-bottom:10px;">BRIM-3 Original</a></li>
<h2><strong>BRIM-3</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Vemurafenib versus Dacarbazine for Metastatic Melanoma with BRAF V600E Mutation".<br/>
The New England Journal of Medicine. 2011.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does vemurafenib improve overall survival and progression-free survival compared with dacarbazine in patients with previously untreated, metastatic melanoma with the BRAF V600E mutation?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Vemurafenib significantly improved rates of overall and progression-free survival compared with dacarbazine in patients with previously untreated, metastatic melanoma harboring the BRAF V600E mutation.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Patients with metastatic melanoma have historically had a poor prognosis. Vemurafenib, a potent inhibitor of mutated BRAF, was evaluated for its therapeutic impact in patients with the BRAF V600E mutation.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the knowledge cutoff for this summary, formal guidelines incorporating vemurafenib's comparative efficacy for the stated patient population have not been specified.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, phase 3, randomized, open-label trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- 675 patients with previously untreated, unresectable stage IIIC or stage IV melanoma that tested positive for the BRAF V600E mutation.<br/>
- Inclusion criteria: ≥18 years, ECOG 0 or 1 performance status, sufficient organ function.<br/>
- Exclusion criteria: Prior cancer within five years, CNS metastases, and other anticancer therapy concurrent use.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Vemurafenib (960 mg orally twice daily) or <br/>
- Dacarbazine (1000 mg/m² intravenously every 3 weeks).<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary outcomes: Rates of overall survival and progression-free survival.<br/>
- Secondary outcomes: Confirmed response rate and duration of response.<br/>
- Key results: Vemurafenib had a 63% relative reduction in the risk of death and a 74% reduction in the risk of death or disease progression compared to dacarbazine.<br/>
- Response rates were 48% for vemurafenib and 5% for dacarbazine.<br/>
- Median follow-up: 3.8 months for vemurafenib and 2.3 months for dacarbazine groups.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Overall survival beyond 7 months in either group was not adequately reported due to insufficient follow-up time.<br/>
- The trial was open-label and not placebo-controlled.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Hoffmann–La Roche.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Original publication in The New England Journal of Medicine.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
